Roivant Sciences (NASDAQ:ROIV) Stock: Insider Melissa Epperly Sells 17,750 Shares

Key Points

• Insider sale: Director Melissa Epperly sold 17,750 Roivant Sciences shares for approximately $640,775 under a pre-arranged Rule 10b5-1 plan, reducing her stake by 54.27% to 14,954 shares.
• Stock and earnings: ROIV traded near $35.78, with a market capitalization of $25.84 billion. The company reported a quarterly loss of $0.26 per share, beating estimates, but revenue of $1.44 million fell short of expectations.
• Analyst sentiment: Analysts maintain a consensus “Moderate Buy” rating with a $45.64 price target; 64.76% of Roivant’s shares are held by institutional investors.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) Director Melissa Epperly sold 17,750 shares of the business's stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $36.10, for a total transaction of $640,775.00. Following the completion of the sale, the director owned 14,954 shares in the company, valued at $539,839.40. This represents a 54.27% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roivant Sciences Trading Up 0.2%

Shares of Roivant Sciences stock traded up $0.06 during mid-day trading on Monday, reaching $35.78. 6,200,484 shares of the stock were exchanged, compared to its average volume of 6,424,994. The company has a market cap of $25.84 billion, a price-to-earnings ratio of -67.51 and a beta of 1.10. The firm has a 50-day simple moving average of $36.58 and a 200 day simple moving average of $32.60. Roivant Sciences Ltd. has a fifty-two week low of $15.25 and a fifty-two week high of $42.50.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. The firm had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. On average, research analysts predict that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ROIV shares. Bank of America reissued a "neutral" rating on shares of Roivant Sciences in a report on Friday, July 31st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, September 24th. Sanford C. Bernstein raised Roivant Sciences to a "strong-buy" rating in a research note on Wednesday, July 29th. Citigroup boosted their price objective on Roivant Sciences from $42.00 to $46.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. Finally, Guggenheim increased their target price on Roivant Sciences from $42.00 to $46.00 and gave the stock a "buy" rating in a report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Roivant Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $45.64.

Institutional Trading of Roivant Sciences

Several hedge funds have recently modified their holdings of the stock. Waverly Advisors LLC raised its position in Roivant Sciences by 2.3% in the 2nd quarter. Waverly Advisors LLC now owns 12,869 shares of the company's stock worth $455,000 after purchasing an additional 291 shares during the last quarter. Fifth Third Bancorp boosted its position in Roivant Sciences by 8.7% in the 1st quarter. Fifth Third Bancorp now owns 4,686 shares of the company's stock valued at $130,000 after buying an additional 376 shares during the last quarter. Bessemer Group Inc. boosted its position in Roivant Sciences by 21.8% in the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company's stock valued at $69,000 after buying an additional 441 shares during the last quarter. Fifth Third Wealth Advisors LLC increased its stake in shares of Roivant Sciences by 4.6% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company's stock valued at $282,000 after buying an additional 445 shares during the period. Finally, Versant Capital Management Inc increased its stake in shares of Roivant Sciences by 13.9% in the 2nd quarter. Versant Capital Management Inc now owns 3,995 shares of the company's stock valued at $141,000 after buying an additional 487 shares during the period. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd. NASDAQ: ROIV is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with serious or underserved diseases. The company operates through a network of subsidiary companies, known as “Vants,” each dedicated to specific therapeutic areas, drug candidates or commercial opportunities.

Roivant's research and development activities have included treatments for immune-mediated diseases, rare disorders, oncology and conditions affecting the nervous system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.